PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Panigrahy, Dipak, Singer, Samuel, Shen, Lucy Q., Butterfield, Catherine E., Freedman, Deborah A., Chen, Emy J., Moses, Marsha A., Kilroy, Susan, Duensing, Stefan, Fletcher, Christopher, Fletcher, Jonathan A., Hlatky, Lynn, Hahnfeldt, Philip, Folkman, Judah, Kaipainen, Arja
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2002
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC151148/
https://ncbi.nlm.nih.gov/pubmed/12370270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI15634
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados